Please use this identifier to cite or link to this item:
|Title:||Antibody-based immunological therapies.|
|Authors:||Scott, Andrew M;Welt, S|
|Affiliation:||Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin, Australia. firstname.lastname@example.org|
|Citation:||Current Opinion in Immunology; 9(5): 717-22|
|Abstract:||Clinical research in the area of antibody-based tumor-targeted therapy has been driven for many years by the prospect of identifying cell surface antigens with sufficient restrictive tissue expression patterns to allow for the selective and specific accumulation of antibody in tumor tissue. Few, if any, such antibody-antigen systems have been identified which can effectively deliver a large fraction of an administered therapeutic agent to metastatic cancer. Despite this limitation, however, a greater understanding of the biological and physiological principles of tumor-targeted therapy has resulted in successful antibody-based therapy of lymphoma, colon cancer and breast cancer in recent clinical trials.|
|Internal ID Number:||9368782|
|Subjects:||Antibodies, Neoplasm.immunology.therapeutic use|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.